Literature DB >> 35300470

Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: medical treatment.

Danujan Sriranganathan1, Jonathan P Segal1, Mayur Garg2,3.   

Abstract

In 2019, the European Crohn's and Colitis Organisation released guidelines for the medical management of Crohn's disease, concerning the induction of remission, the maintenance of remission and the treatment of fistulising perianal disease. This review summarises the key recommendations regarding the use of biologics in these settings. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Crohn's disease

Year:  2021        PMID： 35300470      PMCID： PMC8862488          DOI： 10.1136/flgastro-2021-101881

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


  16 in total

1.  Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.

Authors:  X Roblin; G Boschetti; N Williet; S Nancey; H Marotte; A Berger; J M Phelip; L Peyrin-Biroulet; J F Colombel; E Del Tedesco; S Paul; B Flourie
Journal:  Aliment Pharmacol Ther       Date:  2017-04-27       Impact factor: 8.171

2.  ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.

Authors:  Joana Torres; Stefanos Bonovas; Glen Doherty; Torsten Kucharzik; Javier P Gisbert; Tim Raine; Michel Adamina; Alessandro Armuzzi; Oliver Bachmann; Palle Bager; Livia Biancone; Bernd Bokemeyer; Peter Bossuyt; Johan Burisch; Paul Collins; Alaa El-Hussuna; Pierre Ellul; Cornelia Frei-Lanter; Federica Furfaro; Christian Gingert; Paolo Gionchetti; Fernando Gomollon; Marien González-Lorenzo; Hannah Gordon; Tibor Hlavaty; Pascal Juillerat; Konstantinos Katsanos; Uri Kopylov; Eduards Krustins; Theodore Lytras; Christian Maaser; Fernando Magro; John Kenneth Marshall; Pär Myrelid; Gianluca Pellino; Isadora Rosa; Joao Sabino; Edoardo Savarino; Antonino Spinelli; Laurents Stassen; Mathieu Uzzan; Stephan Vavricka; Bram Verstockt; Janindra Warusavitarne; Oded Zmora; Gionata Fiorino
Journal:  J Crohns Colitis       Date:  2020-01-01       Impact factor: 9.071

3.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

4.  Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.

Authors:  Nicholas A Kennedy; Graham A Heap; Harry D Green; Benjamin Hamilton; Claire Bewshea; Gareth J Walker; Amanda Thomas; Rachel Nice; Mandy H Perry; Sonia Bouri; Neil Chanchlani; Neel M Heerasing; Peter Hendy; Simeng Lin; Daniel R Gaya; J R Fraser Cummings; Christian P Selinger; Charlie W Lees; Ailsa L Hart; Miles Parkes; Shaji Sebastian; John C Mansfield; Peter M Irving; James Lindsay; Richard K Russell; Timothy J McDonald; Dermot McGovern; James R Goodhand; Tariq Ahmad
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-02-27

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.

Authors:  Takayuki Matsumoto; Satoshi Motoya; Kenji Watanabe; Tadakazu Hisamatsu; Hiroshi Nakase; Naoki Yoshimura; Tetsuya Ishida; Shingo Kato; Tomoo Nakagawa; Motohiro Esaki; Masakazu Nagahori; Toshiyuki Matsui; Yuji Naito; Takanori Kanai; Yasuo Suzuki; Masanori Nojima; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Crohns Colitis       Date:  2016-08-26       Impact factor: 9.071

7.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Authors:  Gert Van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Séverine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

8.  Infliximab maintenance therapy for fistulizing Crohn's disease.

Authors:  Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

9.  Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.

Authors:  Vince B C Biemans; C Janneke van der Woude; Gerard Dijkstra; Andrea E van der Meulen-de Jong; Mark Löwenberg; Nanne K de Boer; Bas Oldenburg; Nidhi Srivastava; Jeroen M Jansen; Alexander G L Bodelier; Rachel L West; Annemarie C de Vries; Jeoffrey J L Haans; Dirk de Jong; Frank Hoentjen; Marieke J Pierik
Journal:  Aliment Pharmacol Ther       Date:  2020-05-22       Impact factor: 8.171

10.  Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.

Authors:  R Panaccione; J-F Colombel; W J Sandborn; G D'Haens; Q Zhou; P F Pollack; R B Thakkar; A M Robinson
Journal:  Aliment Pharmacol Ther       Date:  2013-09-22       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.